Adagio Medical Holdings Inc
perceptivelife.comWhat Do They Do?
Develops and sells catheter-based ablation systems for treating ventricular arrhythmias, primarily ventricular tachycardia, to hospitals and medical centers.
10-K for FY2025, filed Mar 27, 2026
Who Are Their Customers?
The company sells its products directly to hospitals and medical centers.
10-K for FY2025, filed Mar 27, 2026The Company generates product revenue primarily from the sale of catheters (the “Consumables”) used with the Company’s consoles. The…View ↗
How Are They Changing?
-
Aug 14, 2026
Nasdaq cited failure to meet its stockholders’ equity requirement
The company said the notice did not immediately affect its Nasdaq listing and that it intends to submit a plan to regain compliance.
Sources
8-K, filed Aug 14, 2026
On August 13, 2026, Adagio Medical Holdings, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department…View ↗
-
Aug 11, 2026
Submitted a U.S. approval application for its ventricular ablation system
The application was supported by results from the FULCRUM-VT pivotal study.
Sources
8-K, filed Aug 11, 2026
Announced pivotal results from the 209-patient FULCRUM-VT trial, which were presented in a late-breaking session at Heart Rhythm Society…View ↗
-
Jun 12, 2026
Nasdaq notified the company of a minimum bid-price deficiency
The stock continued to trade on Nasdaq while the company had time to regain compliance.
Sources
8-K, filed Jun 12, 2026
On June 12, 2026, Adagio Medical Holdings, Inc. (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq…View ↗
-
Apr 27, 2026
Reported six-month results from its pivotal ventricular ablation trial
The results are intended to support the company’s application for U.S. approval.
Sources
8-K, filed Apr 27, 2026
LAGUNA HILLS, CA, April 26, 2026 – Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter…View ↗
Who Do They Compete With?
Competes with Biosense Webster, Johnson & Johnson, Abbott, Medtronic, and Boston Scientific
10-K for FY2025, filed Mar 27, 2026The major players in cardiac EP and advanced ablation catheter markets are Biosense Webster, Inc. (a division of Johnson & Johnson)…View ↗
Loading...
